Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Navidea Biopharmaceuticals, Inc. NAVB
$0.13
-$0 (-2.25%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
4872431.00000000
-
week52high
1.05
-
week52low
0.13
-
Revenue
65652
-
P/E TTM
0
-
Beta
1.49031100
-
EPS
-0.49000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 17 авг 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 22 мая 2020 г. |
| H.C. Wainwright | Buy | Buy | 02 мар 2020 г. |
| H.C. Wainwright | Buy | Buy | 22 ноя 2019 г. |
| Maxim Group | Buy | Buy | 11 июл 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Witter Malcolm G | A | 163888 | 1250 | 30 ноя 2022 г. |
| Scott John K Jr. | A | 8109645 | 1250 | 30 ноя 2022 г. |
| Bhalla Amit | A | 71818 | 1250 | 30 ноя 2022 г. |
| CAPPELLO ALEXANDER L | A | 67727 | 1250 | 30 ноя 2022 г. |
| Wilson Joshua M. | A | 30000 | 30000 | 29 ноя 2022 г. |
| Bhalla Amit | A | 70568 | 2500 | 31 окт 2022 г. |
| CAPPELLO ALEXANDER L | A | 66477 | 2500 | 31 окт 2022 г. |
| Scott John K Jr. | A | 8108395 | 2500 | 31 окт 2022 г. |
| Witter Malcolm G | A | 163888 | 2500 | 31 окт 2022 г. |
| Witter Malcolm G | A | 161388 | 2500 | 30 сент 2022 г. |
Новостная лента
Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2022 Earnings Call Transcript
Seeking Alpha
21 мар 2023 г. в 22:44
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q4 2022 Earnings Conference Call March 22, 2023 5:00 PM ET Company Participants Michael Rosol - SVP & Chief Medical Officer Erika Eves - VP, Finance & Administration and Principal Financial & Accounting Officer Joseph Meyer - Controller Alexander Cappello - Independent Chairman Conference Call Participants Edward English - Private Investor Operator Greetings, and welcome to the Navidea Biopharmaceuticals Fourth Quarter Earnings Call and Business Update. [Operator Instructions].
Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Call Transcript
Seeking Alpha
15 ноя 2022 г. в 20:49
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q3 2022 Earnings Conference Call November 15, 2022 5:00 PM ET Company Participants Michael Rosol – Chief Medical Officer Erika Eves – Vice President-Finance and Administration Conference Call Participants Michael Okunewitch – Maxim Group Mike Rigali – Private Investor Operator Greetings and welcome to the Navidea Biopharmaceuticals' Quarter Three Earnings Call and Business Update. [Operator Instructions] And as a reminder this conference call is being recorded.
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
Business Wire
04 ноя 2022 г. в 07:30
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Tuesday, November 15, 2022 at 5:00 p.m.
Navidea Biopharmaceuticals, Inc. (NAVB) Q2 2022 Earnings Call Transcript
Seeking Alpha
08 сент 2022 г. в 23:46
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q2 2022 Earnings Conference Call September 8, 2022 4:00 PM ET Company Participants Michael Rosol – CMO Alex Cappello - Vice Chair Erika Eves - VP, Finance & Administration Conference Call Participants Michael Okunewitch - Maxim Group Fred Zaino - Keystone Michael Okunewitch - Maxim Group Operator Greetings. Welcome to the Navidea Quarter Two 2022 Earnings Call and Business Update.
Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update
Business Wire
30 авг 2022 г. в 09:30
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the closing of its rights offering and the final results thereof. Navidea received aggregate gross cash proceeds of approximately $6.2 million in the rights offering. If exercised, additional gross proceeds of up to $11.6 million may be received through the exercise of